Exploratory intervention trial of gastric microbiota eradication with vonoprazan, metronidazole, and sitafloxacin to evaluate the improvement of intestinal metaplasia as gastric cancer inhibitory effect

Sue Soichiro0 个研究点目标入组 20 人开始时间: 2023年7月5日最近更新: 2023年11月20日

适应症

试验速览

暂无简介。

•1. Individuals who are considered to have endoscopically suspected intestinal metaplasia based on an endoscopic examination within the past 3 months to 1 year
•2. Individuals who are clinically evaluated as having successfully eradicated H. pylori after eradication therapy or as not currently infected with H. pylori
•3. Individuals who can undergo upper gastrointestinal endoscopy and biopsy before the trial treatment, and upper gastrointestinal endoscopy and biopsy 1 year +- 3 months after the trial treatment

•(1) Individuals who are taking anticoagulants (warfarin potassium, edoxaban, dabigatran, rivaroxaban, apixaban)
•(2) Individuals who are taking antiplatelet drugs (aspirin, ticlopidine, clopidogrel, cilostazol, ethyl icosapentate, prasugrel
•(3) Individuals who are pregnant or may be pregnant
•(4) Individuals who are in the lactation period
•(5) Individuals with a history of allergy to vonoprazan, metronidazole, or sitafloxacin
•(6) Individuals who have received Helicobacter pylori eradication therapy with vonoprazan, metronidazole, and sitafloxacin in the past
•(7) Individuals who are receiving atazanavir sulfate or lopinavir hydrochloride
•(8) Individuals with organic disorders of the brain or spinal cord.

发起方

Sue Soichiro